When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
  • 77 Hits
  • Search Condition : Filter (MeSH = Drug Resistance, Neoplasm*)
Species Resource Title
Human and Animal Cells LNCap.FGC(RCB2144) KCa1.1 K+ Channel Inhibition Overcomes Resistance to Antiandrogens and Doxorubicin in a Human Prostate Cancer LNCaP Spheroid Model.
Human and Animal Cells A549 Elevation of Chemosensitivity of Lung Adenocarcinoma A549 Spheroid Cells by Claudin-2 Knockdown through Activation of Glucose Transport and Inhibition of Nrf2 Signal.
Human and Animal Cells Li-7(RCB1941) Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Human and Animal Cells TE-1(RCB1894) , TE-9(RCB1988) FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma.
Human and Animal Cells A549(RCB0098) Upregulation of Chemoresistance by Mg2+ Deficiency through Elevation of ATP Binding Cassette Subfamily B Member 1 Expression in Human Lung Adenocarcinoma A549 Cells.
Human and Animal Cells GM95(RCB1026) The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs.
Human and Animal Cells , General Microbes TE-8(RCB2098) , TE-10(RCB2099) , JCM8532 Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma.
Drosophila 4236R-1 , DGRC#140092 JNK and Yorkie drive tumor malignancy by inducing L-amino acid transporter 1 in Drosophila.
Human and Animal Cells PC-9(RCB4455) Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
Human and Animal Cells PC-9(RCB4455) Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Human and Animal Cells CACO-2(RCB0988) Mitotic checkpoint regulator RAE1 promotes tumor growth in colorectal cancer.
Human and Animal Cells MKN45(RCB1001) 5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53‑mutated colon cancer cells.
Human and Animal Cells LM8(RCB1450) , OS-RC-2(RCBRCB0735) , Huh-7 , Hep-G2 , HeLa , B16F10(RCB2630) Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp.
Human and Animal Cells LC-2/ad(RCB0440) Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.
Human and Animal Cells KP4(RCB1005) SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy.
Human and Animal Cells HSC-2(RCB1945) ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Human and Animal Cells HeLa(RCB0007) , HSC-3(RCB1975) , OS-RC-2(RCB0735) miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells.
Human and Animal Cells Kato III(RCB2088) , MKN45(RCB1001) Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance.
Human and Animal Cells Ba/F3 Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Human and Animal Cells LK-2(RCB1970) , RERF-LC-AI(RCB0444) , EBC-1(RCB1965) , LC-1/sq-SF(RCB0438) Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.